Comparative Pharmacology
Head-to-head clinical analysis: DYNABAC versus ERYC.
Peer-Reviewed Evidence
Head-to-head clinical analysis: DYNABAC versus ERYC.
DYNABAC vs ERYC
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Dirithromycin is a macrolide antibiotic that binds to the 50S subunit of the bacterial ribosome, specifically to the 23S rRNA, inhibiting peptide chain elongation by blocking the translocation step. It also interferes with the assembly of the 50S ribosomal subunit. This action is primarily bacteriostatic but can be bactericidal at higher concentrations.
Erythromycin acts by binding to the 50S ribosomal subunit of susceptible bacteria, inhibiting protein synthesis by blocking the translocation step.
500 mg orally once daily or 250 mg orally twice daily; usual duration 5-14 days depending on infection
250-500 mg orally every 6 hours or 333-500 mg orally every 8 hours; maximum 4 g/day.
None Documented
None Documented
Terminal elimination half-life is 9–12 hours in adults with normal renal function; may extend to 20–30 hours in severe renal impairment (CrCl <30 mL/min).
2–4 hours in adults with normal renal function; prolonged to 4–8 hours in severe hepatic impairment; does not significantly change in renal failure.
Approximately 65% of a dose is excreted unchanged in the urine via glomerular filtration and tubular secretion; about 15% is excreted unchanged in the bile; fecal elimination accounts for <5%.
Primarily biliary excretion of unchanged drug (60–80%); renal excretion accounts for 10–15% of an oral dose, with minimal fecal elimination (<5%).
Category C
Category C
Macrolide Antibiotic
Macrolide Antibiotic